Dr. @MartinReck2 presents data on 1L PF-08634404 (VEGF-PD1 bispecific) in PD-L1 positive NSCLC at #ASCO26 (SSGJ-707-NSCLC-II-01 study in China). At 10mg/kg, RR 68%, DCR 97%, DOR 18m. Median PFS 12.4m with 12m rate 56%. Encouraging early efficacy signals.
The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC .
A snapshot of what will shape LUNG oncology at #ASCO26 👇
🔹 HARMONI-6 — Ivonescimab + chemo vs tislelizumab + chemo in sqNSCLC (OS, Ph3)
🔹 LIBRETTO-432 — Adjuvant selpercatinib in RET+ NSCLC (EFS, Ph3)
🔹 WU-KONG28 — Sunvozertinib vs chemo in EGFR Ex20ins NSCLC (Ph3)
🔹 OPTITROP-LUNGO5 — Sac-TMT + pembrolizumab in PD-L1+ NSCLC (Ph3)
🔹 TRITON — Tremelimumab/durvalumab/chemo in STK11/KEAP1/KRAS-mut NSCLC
🔹 CROWN 7-year update — Lorlatinib vs crizotinib in ALK+ NSCLC
🔹 LORIN — Neoadjuvant lorlatinib in stage III ALK+ NSCLC
🔹 ACCELERET-LUNG — 1L pralsetinib in RET+ NSCLC
🔹 Silevertinib (BDTX-1535) — Non-classical EGFR-mut NSCLC
🔹 Concurrent CRT + durvalumab in ES-SCLC (Phase III)
Leads
@HHorinouchi@UOzkerim@WeOncologists
Senior Faculty
@GlopesMd@StephenVLiu@peters_solange@CharuAggarwalMD@MartinReck2@christine_lovly
Participating AF
@DrMirallas
Pinging faculty
@bmassutis@UmbertoMalapel1@jillfeldman4@bensolomon1@VanitaNoronha@DrSanjayPopat@DrJNaidoo@Latinamd@JulienMazieres@TerriConneran@BRicciutiMD
Are we seeing a shift in post-TKI treatment for EGFR-mutant NSCLC?
In our Year in Review roundtable, @MartinReck2 discusses the growing role of TROP2-directed ADCs in lung cancer, including data from late-line and earlier-line studies presented for patients progressing after EGFR-TKIs.
The discussion highlights improvements in response and PFS, and the broader question of how TROP2 ADCs may reshape treatment sequencing.
Watch the full discussion with @peters_solange and @charlesrudin ⬇️
https://t.co/Y105J3ZuKH
On behalf of the ESMO Nominations Committee—@MartinReck2@hoperugo , Ulrik Lassen and Nicoletta Colombo—we warmly invite colleagues to nominate those who shine, inspire, lead, and advance excellence in oncology 🌟. Let’s take part and help recognize them together! 🗓️Closes 10 May
Back home from an amazing #ELCC26, I keep reflecting on the true value of scientific meetings:
The best science and education comes only among people who are unite by friendship, mutual respect and a common vision: to improve the care of our patients with lung cancer
See you all in #ELCC27!
@myESMO@IASLC
#ELCC26 Day3 Mini Oral
@MartinReck2 presented "Exploratory Analysis of Participants Without Pathological Complete Response
(pCR) in the KEYNOTE-671 Study of Perioperative Pembrolizumab (Pembro) in Early-Stage #NSCLC After 5 Years of Follow-Up"
@IASLC@myESMO
Are you interested for a deep-dive in early stage #NSCLC including perioperative IO/targeted, ADCs and future trial design?
Don't miss the @myESMO advanced course in #Athens on 23-24th April chaired by @peters_solange , @ElinardouHelena and myself
Register: 👉https://t.co/DRzqXkm9c4
Deadline: 18 March 2026
@OncoAlert #some #LCSM
A new therapeutic opportunity is emerging in MTAP-deleted NSCLC using PRMT5 inhibitors.
During our Year in Review roundtable with @peters_solange, @MartinReck2 and @charlesrudin, we learned how this new class of drugs may target 10% to 30% of all NSCLC cases. These compounds are also being developed in other solid tumors and are now moving into frontline strategies with chemo and potentially IO.
Watch the full roundtable here ⬇️
https://t.co/Xz3CofsSTS
Just out! Delighted to share some work on (IO) refractory Lung Cancer. Thank you for a fantastic cooped! Feasibility and safety of nintedanib in combination with nivolumab in ... https://t.co/nKBE7Y2nPf #LCSM